View source for Biography:Aslam Anis

{{Short description|Bangladeshi-Canadian health economist}}
{{Infobox scientist
| name              = Aslam H. Anis
| birth_date        = {{Birth date and age|1959|04|29}}
| nationality       = Canadian
| alma_mater        = University of Dhaka, Carleton University
| fields            = Health Economics, Health Services Research, Pharmacoeconomics
| spouse            = Janet Anis (née Disanjh)
| awards            = Fellow of the Canadian Academy of Health Sciences (2010)
| workplaces        = University of British Columbia
| known_for         = Health economics
| children          = 2
}}

'''Aslam Anis''' is a Bangladeshi-Canadian health economist whose primary areas of research involvement include [[Biology:Health services research|health services research]], measuring [[Medicine:Patient-reported outcome|patient-reported outcome]]s, Canadian [[Finance:Competition law|competition policy]] in the pharmaceutical industry, and the [[Cost-effectiveness analysis|cost-effectiveness]] of treatments for HIV/AIDS, rheumatoid arthritis, and other conditions.<ref>{{Cite web|last=|first=|date=|title=Aslam Anis|url=http://www.cheos.ubc.ca/people/aslam-anis/|url-status=live|archive-url=https://web.archive.org/web/20160317053106/http://www.cheos.ubc.ca:80/people/aslam-anis/ |archive-date=2016-03-17 |access-date=2020-04-07|website=CHEOS: Centre for Health Evaluation & Outcome Sciences}}</ref><ref name=":0">{{Cite web|title=Aslam Anis|url=https://www.arthritisresearch.ca/aslam-anis/|access-date=2020-11-03|website=Arthritis Research Canada|language=en-US}}</ref><ref name=":3">{{Cite web|title=Aslam Anis|url=https://www.spph.ubc.ca/person/aslam-anis/|access-date=2020-11-03|website=School of Population and Public Health (SPPH)|language=en-US}}</ref>

==Biography==
===Early life===
Aslam Hayat Anis was born in [[Place:Dhaka|Dhaka, Bangladesh]] (then known as Dacca, East Pakistan) to a Bengali family. His father Anis Waiz (1935 – 2003) was a professor of medicine and founding principal of Bangladesh Medical College.<ref>{{Cite news |title=Recalling Major General Anis Waiz|url=https://www.daily-sun.com/post/66426/Recalling-Major-General-Anis-Waiz|access-date=2020-11-03|work=Daily Sun|language=en}}</ref> Anis's mother, Rokaiya Anis (née Ahad) (1935 – 2018), was a clinician in [[Medicine:Obstetrics and gynaecology|gynaecology and obstetrics]] who participated in the [[Religion:Bengali language movement|1952 Language Movement]]. She joined the Pakistan Army as a civilian medical officer and later ran the gynaecology and obstetrics department at the Combined Military Hospital.<ref>{{Cite news |title=Language Movement veteran Dr Col Rokaiya Anis passes away|url=https://www.daily-sun.com/post/285750/Language-Movement-veteran-Dr-Col-Rokaiya-Anis-passes-away|access-date=2020-11-03|work=Daily Sun|language=en}}</ref>

===Academic career===
Anis completed his BSS (Honours) in economics at the University of Dhaka (1981) and his MA and PhD in economics at Carleton University (1983, 1990). He joined the faculty of the University of British Columbia Faculty of Medicine, School of Population and Public Health (then called the Department of Health Care & Epidemiology) in 1995. He was appointed as a full professor in the school in 2005. From 2002 to 2013, Anis served as the director of the Masters of Health Administration (MHA) program in the UBC Faculty of Medicine. He is the National Director of the CIHR Canadian HIV Trials Network and the Director of the Centre for Health Evaluation and Outcome Sciences in {{wipe|Vancouver}}.<ref name=":3" /> Anis is currently the director, ''pro tem'', of the School of Population and Public Health at UBC.<ref>{{Cite web|date=2021-03-09|title=SPPH Welcomes New Director Dr. Aslam Anis|url=https://med-fom-spph.sites.olt.ubc.ca/dr-aslam-anis-director/|access-date=2021-03-15|website=School of Population and Public Health (SPPH)|language=en-US}}</ref>

===Research===
Anis's research spans several areas, including pharmaceutical pricing and regulation, pharmacoeconomic policy, economic decision analysis, measure of work productivity, arthritis, HIV/AIDS, and addictions research. His work has been used to shape economic and health policies across Canada.<ref name=":1">{{Cite web|title=Anis, Aslam|url=https://www.canhepc.ca/en/aslam-anis|access-date=2020-11-03|website=CanHepC - Canadian Network on Hepatitis C|language=en}}</ref><ref name=":0" />

His earliest research in the pharmaceuticals showed that pricing regulations of drug plans were responsible for higher [[Social:Generic drug|generic drug]] prices in Canada. In 1995, as the founding director of the Pharmacoeconomic Initiative of BC, Anis developed a framework under which firms seeking to list drugs on the provincial formulary were required to submit cost-effectiveness data in order to inform the government's funding decision.<ref>{{Cite journal|last1=Anis|first1=Aslam H.|last2=Wen|first2=Quan|date=1998-01-01|title=Price regulation of pharmaceuticals in Canada|url=http://www.sciencedirect.com/science/article/pii/S0167629697000167|journal=Journal of Health Economics|language=en|volume=17|issue=1|pages=21–38|doi=10.1016/S0167-6296(97)00016-7|pmid=10176313|issn=0167-6296}}</ref><ref>{{Cite web|date=2015-01-28|title=OHE Welcomes Dr. Aslam Anis|url=https://www.ohe.org/news/ohe-welcomes-dr-aslam-anis|access-date=2020-11-03|website=www.ohe.org|language=en}}</ref>

Anis was among the first scholars worldwide to demonstrate the cost-effectiveness of anti-retroviral therapy for HIV. This work changed policies governing access to this critical treatment for persons living with HIV/AIDS in British Columbia.<ref name=":1" /><ref>{{Cite journal|last1=Anis|first1=Aslam H.|last2=Guh|first2=Daphne|last3=Hogg|first3=Robert S.|last4=Wang|first4=Xiao-Hua|last5=Yip|first5=Benita|last6=Craib|first6=Kevin J. P.|last7=O’Shaughnessy|first7=Michael V.|last8=Schechter|first8=Martin T.|last9=Montaner|first9=Julio S. G.|date=2000-10-01|title=The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS|url=https://doi.org/10.2165/00019053-200018040-00007|journal=PharmacoEconomics|language=en|volume=18|issue=4|pages=393–404|doi=10.2165/00019053-200018040-00007|pmid=15344307|s2cid=20186375|issn=1179-2027}}</ref>

He led the health economic analysis for  North American Opiate Management Initiative (NAOMI) clinical trial<ref>{{Cite news |last=Luba|first=Frank|title=Why a B.C. doctor says heroin may be better than methadone for addicts|url=http://www.theprovince.com/doctor+says+heroin+better+than+methadone+addicts/6289038/story.html|access-date=2020-11-03|work=The Province|language=en-CA}}</ref> and the Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) clinical trial.<ref name=":2">{{Cite journal|last1=Bansback|first1=Nick|last2=Guh|first2=Daphne|last3=Oviedo-Joekes|first3=Eugenia|last4=Brissette|first4=Suzanne|last5=Harrison|first5=Scott|last6=Janmohamed|first6=Amin|last7=Krausz|first7=Michael|last8=MacDonald|first8=Scott|last9=Marsh|first9=David C.|last10=Schechter|first10=Martin T.|last11=Anis|first11=Aslam H.|date=2018|title=Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial|url=https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14171|journal=Addiction|language=en|volume=113|issue=7|pages=1264–1273|doi=10.1111/add.14171|pmid=29589873|s2cid=4382466|issn=1360-0443}}</ref> These clinical trials were the first of their kind in North America and demonstrated the safety, efficacy, and cost-effectiveness of injectable diacetylmorphine (medical-grade heroin) and [[Chemistry:Hydromorphone|hydromorphone]] (Dilaudid) in treating people with long-term opioid use disorder.<ref name=":2" /><ref>{{Cite journal|last1=Oviedo-Joekes|first1=Eugenia|last2=Brissette|first2=Suzanne|last3=Marsh|first3=David C.|last4=Lauzon|first4=Pierre|last5=Guh|first5=Daphne|last6=Anis|first6=Aslam|last7=Schechter|first7=Martin T.|date=2009-08-20|title=Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction|url= |journal=New England Journal of Medicine|volume=361|issue=8|pages=777–786|doi=10.1056/NEJMoa0810635|issn=0028-4793|pmc=5127701|pmid=19692689}}</ref><ref>{{Cite journal|last1=Oviedo-Joekes|first1=Eugenia|last2=Guh|first2=Daphne|last3=Brissette|first3=Suzanne|last4=Marchand|first4=Kirsten|last5=MacDonald|first5=Scott|last6=Lock|first6=Kurt|last7=Harrison|first7=Scott|last8=Janmohamed|first8=Amin|last9=Anis|first9=Aslam H.|last10=Krausz|first10=Michael|last11=Marsh|first11=David C.|date=2016-05-01|title=Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence|journal=JAMA Psychiatry|language=en|volume=73|issue=5|pages=447–55|doi=10.1001/jamapsychiatry.2016.0109|pmid=27049826|issn=2168-622X|doi-access=free}}</ref> In response to this research and other work, the Canadian government amended regulations to improve access to medically prescribed injectable opioids.<ref>{{Cite web|last1=Mar 26|first1=Kyle Duggan Published on|last2=2018 9:39am|date=2018-03-26|title=Health Canada speeding up access to prescription heroin, methadone|url=https://ipolitics.ca/2018/03/26/health-canada-speeding-up-access-to-prescription-heroin-methadone/|access-date=2020-11-03|website=iPolitics|language=en-US}}</ref>

==Honours, decorations, awards and distinctions==
In 2010, Anis was appointed as a [[Social:Fellow|Fellow]] of the Canadian Academy of Health Sciences.<ref>{{Cite web|title=CAHS Fellows Directory – Canadian Academy of Health Sciences {{!}} Académie canadienne des sciences de la santé|url=https://cahs-acss.ca/directory/|access-date=2020-11-03|language=en-US}}</ref>

==References==
{{reflist}}


{{DEFAULTSORT:Anis, Aslam}}
[[Category:Opioids]]

{{Sourceattribution|Aslam Anis}}